schliessen

Filtern

 

Bibliotheken

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

Summary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities. We aimed to assess use of proven effective secondary preventive drugs (antiplatelet drugs, β blo... Full description

Journal Title: The Lancet (British edition) 2011, Vol.378 (9798), p.1231-1243
Main Author: Yusuf, Salim, Prof
Other Authors: Islam, Shofiqul, MSc , Chow, Clara K, PhD , Rangarajan, Sumathy, MSc , Dagenais, Gilles, Prof , Diaz, Rafael, MD , Gupta, Rajeev, PhD , Kelishadi, Roya, Prof , Iqbal, Romaina, PhD , Avezum, Alvaro, MD , Kruger, Annamarie, Prof , Kutty, Raman, Prof , Lanas, Fernando, MD , Lisheng, Liu, Prof , Wei, Li, Prof , Lopez-Jaramillo, Patricio, Prof , Oguz, Aytekin, MD , Rahman, Omar, Prof , Swidan, Hany, MD , Yusoff, Khalid, Prof , Zatonski, Witold, Prof , Rosengren, Annika, Prof , Teo, Koon K, Prof
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Kidlington: Elsevier Ltd
ID: ISSN: 0140-6736
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_swepub_primary_oai_gup_ub_gu_se_150171
title: Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey
format: Article
creator:
  • Yusuf, Salim, Prof
  • Islam, Shofiqul, MSc
  • Chow, Clara K, PhD
  • Rangarajan, Sumathy, MSc
  • Dagenais, Gilles, Prof
  • Diaz, Rafael, MD
  • Gupta, Rajeev, PhD
  • Kelishadi, Roya, Prof
  • Iqbal, Romaina, PhD
  • Avezum, Alvaro, MD
  • Kruger, Annamarie, Prof
  • Kutty, Raman, Prof
  • Lanas, Fernando, MD
  • Lisheng, Liu, Prof
  • Wei, Li, Prof
  • Lopez-Jaramillo, Patricio, Prof
  • Oguz, Aytekin, MD
  • Rahman, Omar, Prof
  • Swidan, Hany, MD
  • Yusoff, Khalid, Prof
  • Zatonski, Witold, Prof
  • Rosengren, Annika, Prof
  • Teo, Koon K, Prof
subjects:
  • Abridged Index Medicus
  • Adrenergic beta-Antagonists - therapeutic use
  • Adult
  • Aged
  • Angiotensin-Converting Enzyme Inhibitors - therapeutic use
  • Antihypertensive Agents - therapeutic use
  • Biological and medical sciences
  • Cardiovascular agents
  • Cardiovascular Agents - therapeutic use
  • Cardiovascular disease
  • Cardiovascular diseases
  • Cardiovascular Diseases - prevention & control
  • Care and treatment
  • Community
  • Coronary Disease - drug therapy
  • Data Collection
  • Developed Countries
  • Developing Countries
  • Drug use
  • Drug Utilization
  • Economic development
  • Epidemiology
  • Female
  • General aspects
  • Health aspects
  • Households
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
  • Internal Medicine
  • Low income groups
  • Male
  • MEDICAL AND HEALTH SCIENCES
  • Medical sciences
  • MEDICIN OCH HÄLSOVETENSKAP
  • Middle Aged
  • Miscellaneous
  • Platelet Aggregation Inhibitors - therapeutic use
  • Public health. Hygiene
  • Public health. Hygiene-occupational medicine
  • Rural Population
  • Secondary Prevention
  • Socioeconomic factors
  • Stroke
  • Stroke - drug therapy
  • Studies
  • Urban Population
ispartof: The Lancet (British edition), 2011, Vol.378 (9798), p.1231-1243
description: Summary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities. We aimed to assess use of proven effective secondary preventive drugs (antiplatelet drugs, β blockers, angiotensin-converting-enzyme [ACE] inhibitors or angiotensin-receptor blockers [ARBs], and statins) in individuals with a history of coronary heart disease or stroke. Methods In the Prospective Urban Rural Epidemiological (PURE) study, we recruited individuals aged 35–70 years from rural and urban communities in countries at various stages of economic development. We assessed rates of previous cardiovascular disease (coronary heart disease or stroke) and use of proven effective secondary preventive drugs and blood-pressure-lowering drugs with standardised questionnaires, which were completed by telephone interviews, household visits, or on patient's presentation to clinics. We report estimates of drug use at national, community, and individual levels. Findings We enrolled 153 996 adults from 628 urban and rural communities in countries with incomes classified as high (three countries), upper-middle (seven), lower-middle (three), or low (four) between January, 2003, and December, 2009. 5650 participants had a self-reported coronary heart disease event (median 5·0 years previously [IQR 2·0–10·0]) and 2292 had stroke (4·0 years previously [2·0–8·0]). Overall, few individuals with cardiovascular disease took antiplatelet drugs (25·3%), β blockers (17·4%), ACE inhibitors or ARBs (19·5%), or statins (14·6%). Use was highest in high-income countries (antiplatelet drugs 62·0%, β blockers 40·0%, ACE inhibitors or ARBs 49·8%, and statins 66·5%), lowest in low-income countries (8·8%, 9·7%, 5·2%, and 3·3%, respectively), and decreased in line with reduction of country economic status (ptrend
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.7917452
LOCALfalse
PrimoNMBib
record
control
sourceidgale_swepu
recordidTN_cdi_swepub_primary_oai_gup_ub_gu_se_150171
sourceformatXML
sourcesystemPC
galeidA268562536
sourcerecordidA268562536
originalsourceidFETCH-LOGICAL-1730t-50760222069a8ae078bfd0b387d13d1b84f77f805f60e3896013ec890c083c813
addsrcrecordideNqFkn1r1TAUxosobk4_ghIUcYN1Jmmb9iooY8wXGCjOgf-F3OT07mxtck2aO-5388OZ7l6vbgij0JLD73l6Ts6TZU8ZPWCUidenlJU0F3UhdhnbE4yzKi_vZdusrMu8Kusf97PtDbKVPQrhglJaClo9zLY4a2o-4XQ7-3UWgLiWBNDOGuWXZO5hAXZAZ4nxcRZI6zzRyht0CxV07JQnBgOoJERLhnMg2vV9tDgsx8I5zs5ztKkG-6RHYzrYHJU1pHNX63PSRTt4hEB2R5uvZ9-OyekQzXLvDVGpERfmoAdcAIE5GujRdW6GWnUkRL-A5ePsQau6AE_W353s7MPx96NP-cmXj5-PDk9yVhd0yCtaC8o5p2KiGgW0bqatodOiqQ0rDJs2ZVvXbUOrVlAomomgrADdTKimTaEbVuxk-co3XME8TuXcY5-uSjqFchbnMpVmUQaQrKKsHvlXKz6N8DNCGGSPQUPXKQsuBpl-wSkvyjqRz2-RFy56m4YZobLioqAJerGCZqoDibZ1g1d6tJSHXDSV4FUhEnXwHyo948Wl5UKLqX5DsP-PYBoDWgjpFdIChzBTMYSbeLXCddpL8NBuroFROUZSXkdSjnmTjMnrSMoy6Z6tR4zTHsxG9SeDCXi5BlK8VNd6ZTWGv1xZiYqXI_f2VgMaBzUGNQ2K3Z1tvF-pIQVlgeBl0AhWg0GfQiaNwzsd3t1y0B3aMY6XsISwWRyTgUu6Mhk9GLt2KIvfIvclAA
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid896452630
display
typearticle
titleUse of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey
sourceAlma/SFX Local Collection
creatorYusuf, Salim, Prof ; Islam, Shofiqul, MSc ; Chow, Clara K, PhD ; Rangarajan, Sumathy, MSc ; Dagenais, Gilles, Prof ; Diaz, Rafael, MD ; Gupta, Rajeev, PhD ; Kelishadi, Roya, Prof ; Iqbal, Romaina, PhD ; Avezum, Alvaro, MD ; Kruger, Annamarie, Prof ; Kutty, Raman, Prof ; Lanas, Fernando, MD ; Lisheng, Liu, Prof ; Wei, Li, Prof ; Lopez-Jaramillo, Patricio, Prof ; Oguz, Aytekin, MD ; Rahman, Omar, Prof ; Swidan, Hany, MD ; Yusoff, Khalid, Prof ; Zatonski, Witold, Prof ; Rosengren, Annika, Prof ; Teo, Koon K, Prof
creatorcontribYusuf, Salim, Prof ; Islam, Shofiqul, MSc ; Chow, Clara K, PhD ; Rangarajan, Sumathy, MSc ; Dagenais, Gilles, Prof ; Diaz, Rafael, MD ; Gupta, Rajeev, PhD ; Kelishadi, Roya, Prof ; Iqbal, Romaina, PhD ; Avezum, Alvaro, MD ; Kruger, Annamarie, Prof ; Kutty, Raman, Prof ; Lanas, Fernando, MD ; Lisheng, Liu, Prof ; Wei, Li, Prof ; Lopez-Jaramillo, Patricio, Prof ; Oguz, Aytekin, MD ; Rahman, Omar, Prof ; Swidan, Hany, MD ; Yusoff, Khalid, Prof ; Zatonski, Witold, Prof ; Rosengren, Annika, Prof ; Teo, Koon K, Prof ; on behalf of the Prospective Urban Rural Epidemiology (PURE) Study Investigators ; Prospective Urban Rural Epidemiology (PURE) Study Investigators ; Sahlgrenska akademin ; Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin ; Institute of Medicine, Department of Emergeny and Cardiovascular Medicine ; Göteborgs universitet ; Gothenburg University ; Sahlgrenska Academy
descriptionSummary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities. We aimed to assess use of proven effective secondary preventive drugs (antiplatelet drugs, β blockers, angiotensin-converting-enzyme [ACE] inhibitors or angiotensin-receptor blockers [ARBs], and statins) in individuals with a history of coronary heart disease or stroke. Methods In the Prospective Urban Rural Epidemiological (PURE) study, we recruited individuals aged 35–70 years from rural and urban communities in countries at various stages of economic development. We assessed rates of previous cardiovascular disease (coronary heart disease or stroke) and use of proven effective secondary preventive drugs and blood-pressure-lowering drugs with standardised questionnaires, which were completed by telephone interviews, household visits, or on patient's presentation to clinics. We report estimates of drug use at national, community, and individual levels. Findings We enrolled 153 996 adults from 628 urban and rural communities in countries with incomes classified as high (three countries), upper-middle (seven), lower-middle (three), or low (four) between January, 2003, and December, 2009. 5650 participants had a self-reported coronary heart disease event (median 5·0 years previously [IQR 2·0–10·0]) and 2292 had stroke (4·0 years previously [2·0–8·0]). Overall, few individuals with cardiovascular disease took antiplatelet drugs (25·3%), β blockers (17·4%), ACE inhibitors or ARBs (19·5%), or statins (14·6%). Use was highest in high-income countries (antiplatelet drugs 62·0%, β blockers 40·0%, ACE inhibitors or ARBs 49·8%, and statins 66·5%), lowest in low-income countries (8·8%, 9·7%, 5·2%, and 3·3%, respectively), and decreased in line with reduction of country economic status (ptrend <0·0001 for every drug type). Fewest patients received no drugs in high-income countries (11·2%), compared with 45·1% in upper middle-income countries, 69·3% in lower middle-income countries, and 80·2% in low-income countries. Drug use was higher in urban than rural areas (antiplatelet drugs 28·7% urban vs 21·3% rural, β blockers 23·5% vs 15·6%, ACE inhibitors or ARBs 22·8% vs 15·5%, and statins 19·9% vs 11·6%; all p<0·0001), with greatest variation in poorest countries (pinteraction <0·0001 for urban vs rural differences by country economic status). Country-level factors (eg, economic status) affected rates of drug use more than did individual-level factors (eg, age, sex, education, smoking status, body-mass index, and hypertension and diabetes statuses). Interpretation Because use of secondary prevention medications is low worldwide—especially in low-income countries and rural areas—systematic approaches are needed to improve the long-term use of basic, inexpensive, and effective drugs. Funding Full funding sources listed at end of paper (see Acknowledgments).
identifier
0ISSN: 0140-6736
1ISSN: 1474-547X
2EISSN: 1474-547X
3DOI: 10.1016/S0140-6736(11)61215-4
4PMID: 21872920
5CODEN: LANCAO
languageeng
publisherKidlington: Elsevier Ltd
subjectAbridged Index Medicus ; Adrenergic beta-Antagonists - therapeutic use ; Adult ; Aged ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Antihypertensive Agents - therapeutic use ; Biological and medical sciences ; Cardiovascular agents ; Cardiovascular Agents - therapeutic use ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - prevention & control ; Care and treatment ; Community ; Coronary Disease - drug therapy ; Data Collection ; Developed Countries ; Developing Countries ; Drug use ; Drug Utilization ; Economic development ; Epidemiology ; Female ; General aspects ; Health aspects ; Households ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Internal Medicine ; Low income groups ; Male ; MEDICAL AND HEALTH SCIENCES ; Medical sciences ; MEDICIN OCH HÄLSOVETENSKAP ; Middle Aged ; Miscellaneous ; Platelet Aggregation Inhibitors - therapeutic use ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Rural Population ; Secondary Prevention ; Socioeconomic factors ; Stroke ; Stroke - drug therapy ; Studies ; Urban Population
ispartofThe Lancet (British edition), 2011, Vol.378 (9798), p.1231-1243
rights
0Elsevier Ltd
12011 Elsevier Ltd
22015 INIST-CNRS
3Copyright © 2011 Elsevier Ltd. All rights reserved.
4COPYRIGHT 2011 Elsevier B.V.
5Copyright Elsevier Limited Oct 1-Oct 7, 2011
lds50peer_reviewed
citedbyFETCH-LOGICAL-1730t-50760222069a8ae078bfd0b387d13d1b84f77f805f60e3896013ec890c083c813
citesFETCH-LOGICAL-1730t-50760222069a8ae078bfd0b387d13d1b84f77f805f60e3896013ec890c083c813
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24565240$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21872920$$D View this record in MEDLINE/PubMed
2$$Uhttps://gup.ub.gu.se/publication/150171$$DView record from Swedish Publication Index
search
creatorcontrib
0Yusuf, Salim, Prof
1Islam, Shofiqul, MSc
2Chow, Clara K, PhD
3Rangarajan, Sumathy, MSc
4Dagenais, Gilles, Prof
5Diaz, Rafael, MD
6Gupta, Rajeev, PhD
7Kelishadi, Roya, Prof
8Iqbal, Romaina, PhD
9Avezum, Alvaro, MD
10Kruger, Annamarie, Prof
11Kutty, Raman, Prof
12Lanas, Fernando, MD
13Lisheng, Liu, Prof
14Wei, Li, Prof
15Lopez-Jaramillo, Patricio, Prof
16Oguz, Aytekin, MD
17Rahman, Omar, Prof
18Swidan, Hany, MD
19Yusoff, Khalid, Prof
20Zatonski, Witold, Prof
21Rosengren, Annika, Prof
22Teo, Koon K, Prof
23on behalf of the Prospective Urban Rural Epidemiology (PURE) Study Investigators
24Prospective Urban Rural Epidemiology (PURE) Study Investigators
25Sahlgrenska akademin
26Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin
27Institute of Medicine, Department of Emergeny and Cardiovascular Medicine
28Göteborgs universitet
29Gothenburg University
30Sahlgrenska Academy
title
0Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey
1The Lancet (British edition)
addtitleLancet
descriptionSummary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities. We aimed to assess use of proven effective secondary preventive drugs (antiplatelet drugs, β blockers, angiotensin-converting-enzyme [ACE] inhibitors or angiotensin-receptor blockers [ARBs], and statins) in individuals with a history of coronary heart disease or stroke. Methods In the Prospective Urban Rural Epidemiological (PURE) study, we recruited individuals aged 35–70 years from rural and urban communities in countries at various stages of economic development. We assessed rates of previous cardiovascular disease (coronary heart disease or stroke) and use of proven effective secondary preventive drugs and blood-pressure-lowering drugs with standardised questionnaires, which were completed by telephone interviews, household visits, or on patient's presentation to clinics. We report estimates of drug use at national, community, and individual levels. Findings We enrolled 153 996 adults from 628 urban and rural communities in countries with incomes classified as high (three countries), upper-middle (seven), lower-middle (three), or low (four) between January, 2003, and December, 2009. 5650 participants had a self-reported coronary heart disease event (median 5·0 years previously [IQR 2·0–10·0]) and 2292 had stroke (4·0 years previously [2·0–8·0]). Overall, few individuals with cardiovascular disease took antiplatelet drugs (25·3%), β blockers (17·4%), ACE inhibitors or ARBs (19·5%), or statins (14·6%). Use was highest in high-income countries (antiplatelet drugs 62·0%, β blockers 40·0%, ACE inhibitors or ARBs 49·8%, and statins 66·5%), lowest in low-income countries (8·8%, 9·7%, 5·2%, and 3·3%, respectively), and decreased in line with reduction of country economic status (ptrend <0·0001 for every drug type). Fewest patients received no drugs in high-income countries (11·2%), compared with 45·1% in upper middle-income countries, 69·3% in lower middle-income countries, and 80·2% in low-income countries. Drug use was higher in urban than rural areas (antiplatelet drugs 28·7% urban vs 21·3% rural, β blockers 23·5% vs 15·6%, ACE inhibitors or ARBs 22·8% vs 15·5%, and statins 19·9% vs 11·6%; all p<0·0001), with greatest variation in poorest countries (pinteraction <0·0001 for urban vs rural differences by country economic status). Country-level factors (eg, economic status) affected rates of drug use more than did individual-level factors (eg, age, sex, education, smoking status, body-mass index, and hypertension and diabetes statuses). Interpretation Because use of secondary prevention medications is low worldwide—especially in low-income countries and rural areas—systematic approaches are needed to improve the long-term use of basic, inexpensive, and effective drugs. Funding Full funding sources listed at end of paper (see Acknowledgments).
subject
0Abridged Index Medicus
1Adrenergic beta-Antagonists - therapeutic use
2Adult
3Aged
4Angiotensin-Converting Enzyme Inhibitors - therapeutic use
5Antihypertensive Agents - therapeutic use
6Biological and medical sciences
7Cardiovascular agents
8Cardiovascular Agents - therapeutic use
9Cardiovascular disease
10Cardiovascular diseases
11Cardiovascular Diseases - prevention & control
12Care and treatment
13Community
14Coronary Disease - drug therapy
15Data Collection
16Developed Countries
17Developing Countries
18Drug use
19Drug Utilization
20Economic development
21Epidemiology
22Female
23General aspects
24Health aspects
25Households
26Humans
27Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
28Internal Medicine
29Low income groups
30Male
31MEDICAL AND HEALTH SCIENCES
32Medical sciences
33MEDICIN OCH HÄLSOVETENSKAP
34Middle Aged
35Miscellaneous
36Platelet Aggregation Inhibitors - therapeutic use
37Public health. Hygiene
38Public health. Hygiene-occupational medicine
39Rural Population
40Secondary Prevention
41Socioeconomic factors
42Stroke
43Stroke - drug therapy
44Studies
45Urban Population
issn
00140-6736
11474-547X
21474-547X
fulltexttrue
rsrctypearticle
creationdate2011
recordtypearticle
recordideNqFkn1r1TAUxosobk4_ghIUcYN1Jmmb9iooY8wXGCjOgf-F3OT07mxtck2aO-5388OZ7l6vbgij0JLD73l6Ts6TZU8ZPWCUidenlJU0F3UhdhnbE4yzKi_vZdusrMu8Kusf97PtDbKVPQrhglJaClo9zLY4a2o-4XQ7-3UWgLiWBNDOGuWXZO5hAXZAZ4nxcRZI6zzRyht0CxV07JQnBgOoJERLhnMg2vV9tDgsx8I5zs5ztKkG-6RHYzrYHJU1pHNX63PSRTt4hEB2R5uvZ9-OyekQzXLvDVGpERfmoAdcAIE5GujRdW6GWnUkRL-A5ePsQau6AE_W353s7MPx96NP-cmXj5-PDk9yVhd0yCtaC8o5p2KiGgW0bqatodOiqQ0rDJs2ZVvXbUOrVlAomomgrADdTKimTaEbVuxk-co3XME8TuXcY5-uSjqFchbnMpVmUQaQrKKsHvlXKz6N8DNCGGSPQUPXKQsuBpl-wSkvyjqRz2-RFy56m4YZobLioqAJerGCZqoDibZ1g1d6tJSHXDSV4FUhEnXwHyo948Wl5UKLqX5DsP-PYBoDWgjpFdIChzBTMYSbeLXCddpL8NBuroFROUZSXkdSjnmTjMnrSMoy6Z6tR4zTHsxG9SeDCXi5BlK8VNd6ZTWGv1xZiYqXI_f2VgMaBzUGNQ2K3Z1tvF-pIQVlgeBl0AhWg0GfQiaNwzsd3t1y0B3aMY6XsISwWRyTgUu6Mhk9GLt2KIvfIvclAA
startdate2011
enddate2011
creator
0Yusuf, Salim, Prof
1Islam, Shofiqul, MSc
2Chow, Clara K, PhD
3Rangarajan, Sumathy, MSc
4Dagenais, Gilles, Prof
5Diaz, Rafael, MD
6Gupta, Rajeev, PhD
7Kelishadi, Roya, Prof
8Iqbal, Romaina, PhD
9Avezum, Alvaro, MD
10Kruger, Annamarie, Prof
11Kutty, Raman, Prof
12Lanas, Fernando, MD
13Lisheng, Liu, Prof
14Wei, Li, Prof
15Lopez-Jaramillo, Patricio, Prof
16Oguz, Aytekin, MD
17Rahman, Omar, Prof
18Swidan, Hany, MD
19Yusoff, Khalid, Prof
20Zatonski, Witold, Prof
21Rosengren, Annika, Prof
22Teo, Koon K, Prof
general
0Elsevier Ltd
1Elsevier
2Elsevier B.V
3Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
100TT
110TZ
120U~
133V.
147QL
157QP
167RV
177TK
187U7
197U9
207X7
217XB
2288A
2388C
2488E
2588G
2688I
278AF
288AO
298C1
308C2
318FE
328FH
338FI
348FJ
358FK
368G5
37ABUWG
38AN0
39ASE
40AZQEC
41BBNVY
42BEC
43BENPR
44BHPHI
45C1K
46DWQXO
47FPQ
48FYUFA
49GHDGH
50GNUQQ
51GUQSH
52H94
53HCIFZ
54K6X
55K9-
56K9.
57KB0
58KB~
59LK8
60M0R
61M0S
62M0T
63M1P
64M2M
65M2O
66M2P
67M7N
68M7P
69MBDVC
70NAPCQ
71PQEST
72PQQKQ
73PQUKI
74Q9U
75S0X
767X8
77ADTPV
78AOWAS
sort
creationdate2011
titleUse of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey
authorYusuf, Salim, Prof ; Islam, Shofiqul, MSc ; Chow, Clara K, PhD ; Rangarajan, Sumathy, MSc ; Dagenais, Gilles, Prof ; Diaz, Rafael, MD ; Gupta, Rajeev, PhD ; Kelishadi, Roya, Prof ; Iqbal, Romaina, PhD ; Avezum, Alvaro, MD ; Kruger, Annamarie, Prof ; Kutty, Raman, Prof ; Lanas, Fernando, MD ; Lisheng, Liu, Prof ; Wei, Li, Prof ; Lopez-Jaramillo, Patricio, Prof ; Oguz, Aytekin, MD ; Rahman, Omar, Prof ; Swidan, Hany, MD ; Yusoff, Khalid, Prof ; Zatonski, Witold, Prof ; Rosengren, Annika, Prof ; Teo, Koon K, Prof
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1730t-50760222069a8ae078bfd0b387d13d1b84f77f805f60e3896013ec890c083c813
rsrctypearticles
prefilterarticles
languageeng
creationdate2011
topic
0Abridged Index Medicus
1Adrenergic beta-Antagonists - therapeutic use
2Adult
3Aged
4Angiotensin-Converting Enzyme Inhibitors - therapeutic use
5Antihypertensive Agents - therapeutic use
6Biological and medical sciences
7Cardiovascular agents
8Cardiovascular Agents - therapeutic use
9Cardiovascular disease
10Cardiovascular diseases
11Cardiovascular Diseases - prevention & control
12Care and treatment
13Community
14Coronary Disease - drug therapy
15Data Collection
16Developed Countries
17Developing Countries
18Drug use
19Drug Utilization
20Economic development
21Epidemiology
22Female
23General aspects
24Health aspects
25Households
26Humans
27Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
28Internal Medicine
29Low income groups
30Male
31MEDICAL AND HEALTH SCIENCES
32Medical sciences
33MEDICIN OCH HÄLSOVETENSKAP
34Middle Aged
35Miscellaneous
36Platelet Aggregation Inhibitors - therapeutic use
37Public health. Hygiene
38Public health. Hygiene-occupational medicine
39Rural Population
40Secondary Prevention
41Socioeconomic factors
42Stroke
43Stroke - drug therapy
44Studies
45Urban Population
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Yusuf, Salim, Prof
1Islam, Shofiqul, MSc
2Chow, Clara K, PhD
3Rangarajan, Sumathy, MSc
4Dagenais, Gilles, Prof
5Diaz, Rafael, MD
6Gupta, Rajeev, PhD
7Kelishadi, Roya, Prof
8Iqbal, Romaina, PhD
9Avezum, Alvaro, MD
10Kruger, Annamarie, Prof
11Kutty, Raman, Prof
12Lanas, Fernando, MD
13Lisheng, Liu, Prof
14Wei, Li, Prof
15Lopez-Jaramillo, Patricio, Prof
16Oguz, Aytekin, MD
17Rahman, Omar, Prof
18Swidan, Hany, MD
19Yusoff, Khalid, Prof
20Zatonski, Witold, Prof
21Rosengren, Annika, Prof
22Teo, Koon K, Prof
23on behalf of the Prospective Urban Rural Epidemiology (PURE) Study Investigators
24Prospective Urban Rural Epidemiology (PURE) Study Investigators
25Sahlgrenska akademin
26Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin
27Institute of Medicine, Department of Emergeny and Cardiovascular Medicine
28Göteborgs universitet
29Gothenburg University
30Sahlgrenska Academy
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9News PRO
10Pharma and Biotech Premium PRO
11Global News & ABI/Inform Professional
12ProQuest Central (Corporate)
13Bacteriology Abstracts (Microbiology B)
14Calcium & Calcified Tissue Abstracts
15Nursing & Allied Health Database
16Neurosciences Abstracts
17Toxicology Abstracts
18Virology and AIDS Abstracts
19Health & Medical Collection
20ProQuest Central (purchase pre-March 2016)
21Biology Database (Alumni Edition)
22Healthcare Administration Database (Alumni)
23Medical Database (Alumni Edition)
24Psychology Database (Alumni)
25Science Database (Alumni Edition)
26STEM Database
27ProQuest Pharma Collection
28Public Health Database
29Lancet Titles
30ProQuest SciTech Collection
31ProQuest Natural Science Collection
32Hospital Premium Collection
33Hospital Premium Collection (Alumni Edition)
34ProQuest Central (Alumni) (purchase pre-March 2016)
35Research Library (Alumni Edition)
36ProQuest Central (Alumni Edition)
37British Nursing Database
38British Nursing Index
39ProQuest Central Essentials
40Biological Science Collection
41eLibrary
42ProQuest Central
43Natural Science Collection
44Environmental Sciences and Pollution Management
45ProQuest Central Korea
46British Nursing Index (BNI) (1985 to Present)
47Health Research Premium Collection
48Health Research Premium Collection (Alumni)
49ProQuest Central Student
50Research Library Prep
51AIDS and Cancer Research Abstracts
52SciTech Premium Collection
53British Nursing Index
54Consumer Health Database (Alumni Edition)
55ProQuest Health & Medical Complete (Alumni)
56Nursing & Allied Health Database (Alumni Edition)
57ProQuest Newsstand Professional
58ProQuest Biological Science Collection
59Consumer Health Database
60Health & Medical Collection (Alumni Edition)
61Healthcare Administration Database
62Medical Database
63Psychology Database
64Research Library
65Science Database
66Algology Mycology and Protozoology Abstracts (Microbiology C)
67Biological Science Database
68Research Library (Corporate)
69Nursing & Allied Health Premium
70ProQuest One Academic Eastern Edition
71ProQuest One Academic
72ProQuest One Academic UKI Edition
73ProQuest Central Basic
74SIRS Editorial
75MEDLINE - Academic
76SwePub
77SwePub Articles
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Yusuf, Salim, Prof
1Islam, Shofiqul, MSc
2Chow, Clara K, PhD
3Rangarajan, Sumathy, MSc
4Dagenais, Gilles, Prof
5Diaz, Rafael, MD
6Gupta, Rajeev, PhD
7Kelishadi, Roya, Prof
8Iqbal, Romaina, PhD
9Avezum, Alvaro, MD
10Kruger, Annamarie, Prof
11Kutty, Raman, Prof
12Lanas, Fernando, MD
13Lisheng, Liu, Prof
14Wei, Li, Prof
15Lopez-Jaramillo, Patricio, Prof
16Oguz, Aytekin, MD
17Rahman, Omar, Prof
18Swidan, Hany, MD
19Yusoff, Khalid, Prof
20Zatonski, Witold, Prof
21Rosengren, Annika, Prof
22Teo, Koon K, Prof
aucorp
0on behalf of the Prospective Urban Rural Epidemiology (PURE) Study Investigators
1Prospective Urban Rural Epidemiology (PURE) Study Investigators
2Sahlgrenska akademin
3Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin
4Institute of Medicine, Department of Emergeny and Cardiovascular Medicine
5Göteborgs universitet
6Gothenburg University
7Sahlgrenska Academy
formatjournal
genrearticle
ristypeJOUR
atitleUse of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey
jtitleThe Lancet (British edition)
addtitleLancet
date2011
risdate2011
volume378
issue9798
spage1231
epage1243
pages1231-1243
issn
00140-6736
11474-547X
eissn1474-547X
codenLANCAO
abstractSummary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities. We aimed to assess use of proven effective secondary preventive drugs (antiplatelet drugs, β blockers, angiotensin-converting-enzyme [ACE] inhibitors or angiotensin-receptor blockers [ARBs], and statins) in individuals with a history of coronary heart disease or stroke. Methods In the Prospective Urban Rural Epidemiological (PURE) study, we recruited individuals aged 35–70 years from rural and urban communities in countries at various stages of economic development. We assessed rates of previous cardiovascular disease (coronary heart disease or stroke) and use of proven effective secondary preventive drugs and blood-pressure-lowering drugs with standardised questionnaires, which were completed by telephone interviews, household visits, or on patient's presentation to clinics. We report estimates of drug use at national, community, and individual levels. Findings We enrolled 153 996 adults from 628 urban and rural communities in countries with incomes classified as high (three countries), upper-middle (seven), lower-middle (three), or low (four) between January, 2003, and December, 2009. 5650 participants had a self-reported coronary heart disease event (median 5·0 years previously [IQR 2·0–10·0]) and 2292 had stroke (4·0 years previously [2·0–8·0]). Overall, few individuals with cardiovascular disease took antiplatelet drugs (25·3%), β blockers (17·4%), ACE inhibitors or ARBs (19·5%), or statins (14·6%). Use was highest in high-income countries (antiplatelet drugs 62·0%, β blockers 40·0%, ACE inhibitors or ARBs 49·8%, and statins 66·5%), lowest in low-income countries (8·8%, 9·7%, 5·2%, and 3·3%, respectively), and decreased in line with reduction of country economic status (ptrend <0·0001 for every drug type). Fewest patients received no drugs in high-income countries (11·2%), compared with 45·1% in upper middle-income countries, 69·3% in lower middle-income countries, and 80·2% in low-income countries. Drug use was higher in urban than rural areas (antiplatelet drugs 28·7% urban vs 21·3% rural, β blockers 23·5% vs 15·6%, ACE inhibitors or ARBs 22·8% vs 15·5%, and statins 19·9% vs 11·6%; all p<0·0001), with greatest variation in poorest countries (pinteraction <0·0001 for urban vs rural differences by country economic status). Country-level factors (eg, economic status) affected rates of drug use more than did individual-level factors (eg, age, sex, education, smoking status, body-mass index, and hypertension and diabetes statuses). Interpretation Because use of secondary prevention medications is low worldwide—especially in low-income countries and rural areas—systematic approaches are needed to improve the long-term use of basic, inexpensive, and effective drugs. Funding Full funding sources listed at end of paper (see Acknowledgments).
copKidlington
pubElsevier Ltd
pmid21872920
doi10.1016/S0140-6736(11)61215-4